Yes, the experts have known for some time that the side effects are cumulative when yervoy (ctla-4) and opdivo (or any other CI) are combined.
More institutions will pour into NWBO as sarcoma, lung and other responses continue to mature. As you know, there is the phase II DCVax-L adjuvant trial that could be released at any given moment. There is the phase III 1st interim analysis and enrollment completion, which should be....interesting. There is the H.E. negotiation. The beginning of the phase II Direct trials, their final design and FDA designations. Each one of these steps will pick up more and more institutions. Right now, I think NWBO/Woodford might speak to some analysts about taking a serious look at covering NWBO -- that's been a long time coming.
News 
Market Data 
Discover 
